Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Official Title

Palifermin Treatment of Toxic Epidermal Necrolysis

Brief Summary

      To test the ability of palifermin (a recombinant human keratinocyte growth factor) to
      decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis
      and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is
      extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal
      tract, respiratory and genitourinary systems.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Time-to-cutaneous Re-epithelialization

Secondary Outcome

 Time-to-mucosal Re-epithelialization


Toxic Epidermal Necrolysis



Study Arms / Comparison Groups

Description:  Palifermin 60 micrograms/kg/day IV for 3 consecutive days


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2010

Completion Date

December 2014

Primary Completion Date

December 2014

Eligibility Criteria

        Inclusion Criteria:

          -  Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in
             more advanced disease necrosis of the entire epidermis

          -  Epidermal detachment or erythematous to purpuric macules involving more than 10% of
             body surface area in addition to involvement of the oropharynx; there may be further
             involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract,
             respiratory and genitourinary epithelia

          -  Age of 18 years old or older

          -  The patient is expected to survive longer than 48 hours

        Exclusion Criteria:

          -  Skin detachment above 90% of the body surface area

          -  Skin detachment has not progressed during the previous 48 hours

          -  A positive serum pregnancy test

          -  Age < 18 years old

          -  Known hematologic or solid organ malignancy




18 Years - N/A

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Brett King


 Swedish Orphan Biovitrum

Study Sponsor

, , 

Verification Date

October 2016